BRIEF published on 09/19/2024 at 18:05, 1 year 7 months ago ABIVAX: Number of shares and voting rights as of August 31, 2024 Euronext Paris Share Capital Voting Rights Biotechnology Abivax
BRIEF published on 09/09/2024 at 23:01, 1 year 7 months ago Statement by Marc de Garidel on Abivax's 2024 Half-Year Financial Report Financial Report Abivax Transparency IFRS Heritage
BRIEF published on 09/09/2024 at 22:40, 1 year 7 months ago ABIVAX presents its 2024 half-year results Cybersecurity Abivax Half-year Results Internal Control Failures
BRIEF published on 09/09/2024 at 22:06, 1 year 7 months ago Abivax financial results for the first half of 2024 Financial Results Biotechnology Abivax First Half Of 2024 Immune Mechanisms
PRESS RELEASE published on 09/09/2024 at 22:01, 1 year 7 months ago Abivax presents first-half 2024 financial results Abivax presents first-half 2024 financial results with a cash balance of EUR 222M at June 30, 2024. The company focuses on developing therapies for chronic inflammatory diseases Financial Results Abivax Therapeutics Chronic Inflammatory Diseases EUR 222M
BRIEF published on 08/29/2024 at 18:05, 1 year 8 months ago ABIVAX: Status of shares and voting rights as of July 31, 2024 Euronext Paris Voting Rights Actions Abivax Regulatory
BRIEF published on 08/06/2024 at 08:35, 1 year 8 months ago Abivax Reaches Key Milestone with Recruitment of 600 Patients for Phase 3 ABTECT Trial Patient Recruitment Abivax Obefazimod Ulcerative Colitis Clinical Test
PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Abivax announces ABTECT Phase 3 Trial surpasses 600-patient enrollment milestone, on track for full enrollment by early Q1 2025. Trial trends align with previous observations Abivax Obefazimod Ulcerative Colitis ABTECT Phase 3 Trial Enrollment Milestone
BRIEF published on 07/23/2024 at 18:05, 1 year 9 months ago ABIVAX: Number of shares and voting rights as of June 30, 2024 Voting Rights Euronext Actions AMF Abivax
BRIEF published on 07/23/2024 at 18:05, 1 year 9 months ago ABIVAX: Half-yearly review of the liquidity contract as of June 30, 2024 Liquidity Contract Actions Financial Transactions Abivax First Half Of 2024
Published on 05/02/2026 at 21:00, 22 hours 55 minutes ago GECC Subsidiary Provides Update on its Lawsuit for Damages Against the Lender of the Atmosphere Project
Published on 05/02/2026 at 01:30, 1 day 18 hours ago Uraniumx Reports Strong Financial Position Ahead of Spring Drill Program
Published on 05/02/2026 at 00:50, 1 day 19 hours ago CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants
Published on 05/02/2026 at 00:00, 1 day 19 hours ago Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Published on 05/02/2026 at 00:00, 1 day 19 hours ago Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Published on 05/03/2026 at 04:45, 15 hours 9 minutes ago GWM Unveils World-Class Safety & Testing Facilities: Safety Built on Data, Not Hype
Published on 05/02/2026 at 15:35, 1 day 4 hours ago Ecuador's banana sector renews labor agreement, with jobs meeting global standards
Published on 04/30/2026 at 20:00, 2 days 23 hours ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:00, 3 days ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 3 days 1 hour ago Minutes of the Combined General Meeting held on April 30, 2026
